ThermoDox, Celsion’s temperature-sensitive liposomal encapsulation of common cancer drug doxorubicin, allows focused, concentrated delivery of the drug to the tumor target. The phase I trial, which is being
The investigator-sponsored trial is being conducted at specialist centers in Europe and Egypt, which contains the highest prevalence of hepatitis C in the world. It will assess the
The primary objective of this study is to evaluate the safety and tolerability of single- and multiple-dose applications of Indaflex, a novel formulation of indomethacin cream. The secondary
The product, named Locteron, combines OctoPlus’ proprietary biodegradable PolyActive drug delivery technology with Biolex’ BLX-883, a recombinant alfa interferon produced in its proprietary LEX System. Locteron is designed
The objectives of the phase II program are to evaluate the pharmacokinetics, efficacy, and safety of repetitive applications of Durect’s sufentanil patch in chronic pain patients for a
The new access avenue aims to enable physicians to use a wireless personal digital assistant (PDA), BlackBerry or smartphone to remotely access health information resources in real-time from
Proligo, a global supplier of key genomics research tools including custom DNA, custom RNA and phosphoramidite raw materials used for DNA and RNA synthesis, had 2004 sales of
Efficacy results with indiplon MR tablets demonstrated a highly statistically significant and clinically relevant improvement on the primary endpoint of patient reported total sleep time, as compared to
Using its integrated chemical and pharmaceutical development platform, EVOdevelop, Evotec OAI will complete the full validation of the process to AMD 3100, including process R&D, analytical work and
Diatos NV focuses its research on anticancer prodrugs, based on one of Diatos’s two core technology platforms, known as tumor-selective prodrug technology (TSP). The funding of E650,000 over
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.